The National Biosafety Authority (NBA) has approved the trial of an HIV vaccine and Malaria control to be undertaken by the Centre for Infectious Disease Research in Zambia (CIDRZ) and Macha Research Trust respectively.
NBA Chief Executive Officer (CEO) Lackson Tonga said the permit granted to CIDRZ is for conducting research trials on the safety and immunogenicity of HVTN 120/ALVAC in Lusaka while, the malaria control will be done at Macha Research Trust, Choma in Southern Province.
In a statement released to ZANIS in Lusaka yesterday by NBA Communications Officer Sandra Lombe, Mr. Tonga said his authority approved the permits following the two applicants meeting the required set standards tabulated in section 18 of the Biosafety Act No. 7 of 2007.
“The NBA Board, during the 4th quarter meeting for the year 2017, approved the permit application for CIDRZ. The vaccine trials will be conducted in Matero, Lusaka and the permit is valid for three years,” said Mr. Tonga
He said CIDRZ’s Phase 1 clinical trial will evaluate the safety and immunogenicity of the genetically modified vaccine ALVAC-HIV (vCP2438) in healthy HIV-uninfected adult participants.
Mr. Tonga further stated that the Scientific Advisory Committee (SAC) of the NBA met in August last year and was satisfied after reviewing the application as having met the expected safety threshold demanded by collaborating partners such as Zambia Medicines Regulatory Authority and the Biomedical Research Ethics Committee.
He said Macha Research Trust will carry out research in a contained facility at the Research Trust on Malaria control prospects with engineered symbiotic bacteria from mosquitoes.
Mr. Tonga further noted that the Authority had reviewed all applications it had received in 2017 and those that met the required guidelines and standards had been issued with permits while, others had been requested to submit further details to allow for thorough risk assessment.